Adam Chitwood is a former Managing Editor at Collider, where he covered film and television with a focus on interviews, features, and industry analysis. The saga of Ridley Scott’s Prometheus sequel ...
Pharma goliath, Merck MRK and Prometheus Biosciences, Inc RXDX, together announced entering a definitive agreement where the former is set to acquire the latter, through a subsidiary for $200 per ...
Having some free time following the $10.8 billion buyout of Prometheus Biosciences made Mark McKenna realize he had some “unfinished business.” Prometheus had managed to create a therapeutic that ...
April 16 (Reuters) - Merck & Co said on Sunday it will buy Prometheus Biosciences Inc for about $10.8 billion, picking up a promising experimental treatment for ulcerative colitis and Crohn's disease ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback